Cambridge, UK, December 10th, 2024 – CellCentric, a clinical-stage biotechnology company, today announces new data at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. Dr. Emma Searle, Consultant Hematologist at The Christie NHS Foundation Trust, presented promising results from its Phase I/II trial of inobrodib in combination with pomalidomide and dexamethasone (InoPd) in patients with relapsed or refractory multiple myeloma (RRMM).
The data shared at ASH highlights the encouraging efficacy and manageable safety profile of inobrodib in combination with pomalidomide and dexamethasone in heavily pre-treated RRMM patients, including those who have failed multiple prior treatments. Key findings include:
- 75% ORR: Responses were observed across all dosing levels, with the highest dose cohort showing an overall response rate (ORR) of 75% and a median duration of response (mDOR) of 9.7 months (ongoing).
- Reversal of Pomalidomide Refractoriness: Inobrodib demonstrated the potential to reverse pomalidomide refractoriness, providing another option for patients previously resistant to this therapy.
- Eliciting Complete Responses in Pomalidomide-Naïve Patients: InoPd was able to induce stringent complete responses (sCR) and minimal residual disease-negative (MRDneg) status in patients who had not been previously treated with pomalidomide, offering a promising option for earlier-line treatment.
- Activity Post T-Cell Engagers: The data also showed evidence of InoPd’s activity in patients who had been previously treated with T-cell engager therapies, supporting its potential role following treatment with this important class.
Dr. Emma Searle commented, “The results we presented today at ASH are highly encouraging, particularly for patients who have limited treatment options. Inobrodib is an oral drug with a novel mechanism of action that can complement existing therapies. We have shown its ability to reverse pomalidomide refractoriness, as well as achieve impressive responses even in patients that have previously had a T-cell engager agent and relapsed.”
No new safety concerns were identified across the three dosing cohorts, reinforcing the manageable safety profile of inobrodib. In preparation for pivotal trials, CellCentric has just initiated a randomized dose expansion study of InoPd.
About inobrodib
Inobrodib is a novel investigational treatment for people with cancer. Delivered as an oral capsule, it is easy for patients to take. With over 400 people now treated, the safety profile is well characterised; it may be used by those who are unable to access or tolerate other types of treatment.
About CellCentric CellCentric is an innovative UK-based biotechnology company with offices and operations in Cambridge, Manchester and Boston. The company was spun out from the University of Cambridge, by pioneering developmental biologist Professor Azim Surani FRS, CBE, who wanted to further explore the potential of targeting cell fate control mechanisms. The company is now wholly focused on progressing its pioneering p300/CBP inhibitor, inobrodib, for people with cancer.
